REGEN-COV as the First Line of Defense-A Single-Centre Experience.

Area of Science:

• Infectious Diseases
• Virology
• Immunology

Background:

• Casirivimab-imdevimab (REGEN-COV) is a neutralizing antibody cocktail effective against SARS-CoV-2 variants.
• Previous studies demonstrated REGEN-COV's efficacy in preventing COVID-19 progression and severe outcomes.
• The Delta variant was globally dominant during the study period.

Purpose of the Study:

• To evaluate the real-world effectiveness of REGEN-COV in a single center.
• To compare hospitalization and mortality rates between REGEN-COV treated and untreated patients.

Main Methods:

• Retrospective observational study of adult patients from June 2021 to January 2022.
• REGEN-COV group (n=69) vs. non-REGEN-COV group (n=137).
• Primary endpoint: hospitalization; Secondary endpoints: all-cause mortality and ICU admission.

Main Results:

• Hospitalization occurred in 15.9% of the REGEN-COV group versus 85.4% in the non-REGEN-COV group (p < 0.001).
• Mortality was 2.9% in the REGEN-COV group compared to 21.9% in the non-REGEN-COV group.
• Kaplan-Meier survival analysis showed a significant difference in survival between groups (log-rank p < 0.001).

Conclusions:

• REGEN-COV use was associated with reduced hospitalization and better outcomes in high-risk COVID-19 patients with specific SARS-CoV-2 variants.
• Variant-specific effectiveness may limit the generalizability of findings.
• Further research is needed to confirm these findings across diverse populations and variants.